Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia

You may also be interested in...



FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia

FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.

FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia

FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.

Advisory Committee Conflict Of Interest Policy Simplified In Draft Guidance

FDA presents a consolidated, step-by-step policy to determine eligibility of possible advisory committee participants.

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel